Chaim Gilon,

Institute of Chemistry, The Hebrew University, Jerusalem, Israel (chaimgilon@gmail.com)

Short CV: Date of start as faculty member in HUJI: 1976 Current academic degree: Professor Emeritus Active. Born: 17-11-1937

Research activities.

Molecular mechanism of Memory Recently, based on existing literature and basic principles of chemistry and biology, we suggest a credible model that describes the molecular basis of memory.

Development and application of technologies for the conversion of bioactive peptides and active regions in proteins into drugs. Over the years we have developed technologies such as: Backbone Cyclization, Cycloscan, Combinatorial Cycloscan and Helix Walk. These technologies are based on the design and synthesis of libraries with conformational diversity based on a parent active peptide or active region in protein and screening them for their biological activity, metabolic stability and intestinal bioavailability. From these libraries the most active, selective, metabolically stable and orally bioavailable peptidomimetic with drug like properties is selected for in vivo preclinical studies. Few recent examples for the application of these technologies: (1) discovery of a novel mocrocyclic, orally available, potent inhibitor of HIV-1 replication in cells, a drug lead for AIDS (2) potent orally available, mimetic of α -MSH that inhibits weight gain in mice. (3) Extremely highly potent (pictogram/animal) drug lead that cure rheumatoid arthritis in mice. (4) Development of agonist and antagonists based on NK peptides that enhance or block fish reproduction

Signal Transduction Therapy. We have invented this concept in 1985. Recent applications: (1) in-vivo active inhibitor of the GPCR CC2 receptor dimerization which is the key protein in multiple sclerosis (2) potent substrate inhibitor of PKB, a key protein in the signal transduction of many cancers.

Publications and Patents. 200 publications in peer review journals. 40 patents. 8 articles were cited more than 250 times.

5/15/2010		5 115		
	Chaim Gilon		Google Scholar	
	Professor Emeritus Active, Institute of Chemistry, HUJI Chemistry of memory, peptide and protein drugs	Citation indices Citations h-index i10-index	All Si 8950 49 139	nce 2011 2060 22 54
Title 1–20			Cited by	Year
Conformational design of bioactive peptides H Kessler, R Konat, M Kurz, C Gilon Collection of Czechoslovak Chemical Communications 1, 86-94				2016
The Molecular Basis of Neural Memory. Part 6: Chemical coding of logical and emotive modes G Marx, C Gilon International Journal of Neurology Research 2 (2), 259-268				2016
The Molecular Basis of Neural Memory. Part 4. "Binary" Computation vs "Multinary" Mentation G Marx, C Gilon Neuroscience and Biomedical Engineering 4 (1), 14-24				2016
REMODELING	g, C Gilon, A Hoffman	DNE		2016
transport and e J Fanous, A Swed	he S, S conformation in diverse pharmacological pro entry inhibition activity of novel anti-HIV drug lead d, S Joubran, M Hurevich, E Britan-Rosich, M Kotler, al of pharmaceutics 495 (2), 660-663	ocesses: Intestinal		2015
UK Marelli, O Ova	nds: A Key for Intestinal Permeability of Peptides? Idia, AO Frank, J Chatterjee, C Gilon, A Hoffman, Opean Journal 21 (43), 15148-15152		2	2015
	udies of malonic acid-mediated in situ acylation aoum, TK Roy, C Gilon, RB Gerber, A Friedler 04 (5), 495-505			2015
Erosive Arthritis S Ling, Y Liu, J Fu	e–Antagonistic Ligands: A New Therapeutic Strategy s J, A Colletta, C Gilon, J Holoshitz atology 67 (8), 2061-2070	y in Mice With		2015
D28k binding s 23 (2013) 1806 I Levi, Y Eskira, M	o "Inhibition of inositol monophosphatase (IMPase) a ite: Molecular and behavioural aspects"[Eur. Neurop 5–1815] I Eisenstein, C Gilon, A Hoffman, Y Tal-Gan, J Fanous, sychopharmacology 11 (25), 2185			2015

Title 1–20	Cited by	Year
A tandem in situ peptide cyclization through trifluoroacetic acid cleavage K Chandra, TK Roy, DE Shalev, A Loyter, C Gilon, RB Gerber, A Friedler Angewandte Chemie 126 (36), 9604-9609	7	2014
Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development M Hurevich, A Talhami, D E Shalev, C Gilon Current topics in medicinal chemistry 14 (15), 1842-1863	1	2014
Stabilized Peptide Helices For Inhibiting Dimerization Of Chemokine C Motif Receptor 2 (CCR2) C Gilon, M Ratner-Hurevich, M Hurevich US Patent App. 14/339,027		2014
Compositions and methods for inducing an immune response J Holoshitz, S Ling, X Pi, D De Almeida, C Gilon, A Hoffman US Patent 8,658,603	1	2014
The molecular basis of memory. Part 3: tagging with "emotive" neurotransmitters G Marx, C Gilon Frontiers in aging neuroscience 6	2	2014
A highly efficient in situ N-acetylation approach for solid phase synthesis K Chandra, TK Roy, JN Naoum, C Gilon, RB Gerber, A Friedler Organic & biomolecular chemistry 12 (12), 1879-1884	7	2014
Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: Molecular and behavioral aspects I Levi, Y Eskira, M Eisenstein, C Gilon, A Hoffman, Y Talgan, J Fanous, European Neuropsychopharmacology 23 (12), 1806-1815	1	2013
Cyclic peptides: Powerful chemical tools to elucidate biological pathways Y Tal-Gan, A Levitzki, C Gilon, HE Blackwell ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 246		2013
A Small Shared Epitope–Mimetic Compound Potently Accelerates Osteoclast- Mediated Bone Damage in Autoimmune Arthritis J Fu, S Ling, Y Liu, J Yang, S Naveh, M Hannah, C Gilon, Y Zhang, The Journal of Immunology 191 (5), 2096-2103	4	2013
Backbone cyclic helix mimetic of chemokine (C–C motif) receptor 2: A rational approach for inhibiting dimerization of G protein-coupled receptors M Hurevich, M Ratner-Hurevich, Y Tal-Gan, DE Shalev, SZ Ben-Sasson, Bioorganic & medicinal chemistry 21 (13), 3958-3966	2	2013
A small shared epitope-mimetic compound potently accelerates osteoclast-mediated bone damage in autoimmune arthritis (P3090) J Fu, S Ling, Y Liu, M Hannah, C Gilon, J Holoshitz The Journal of Immunology 190 (1 Supplement), 43.8-43.8		2013